Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 3:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 233 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Itraconazole (Sporanox) Clear all

Conditions: Pharmacokinetics
Interventions: DS-8500a, Itraconazole; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Barrett Oesophagitis With Dysplasia
Interventions: Itraconazole in capsule form, Itraconazole in solution form; Drug
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Systemic Fungal Infections
Interventions: Parenteral micafungin application, Other parenteral antifungal drugs; Drug
Lead sponsor: Astellas Pharma Europe B.V.; Industry
Eligibility: Not listed
Enrollment: 40,110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 6
States / cities: Baltimore, Maryland • Boston, Massachusetts • Ann Arbor, Michigan + 3 more

Conditions: Esophageal Cancer
Interventions: Itraconazole; Drug
Lead sponsor: Dallas VA Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Healthy
Interventions: 100mg IkT-148009 Wet, 200 mg Itraconazole, 100mg IkT-148009 Dry, 50mg IkT-148009 Wet; Drug
Lead sponsor: ABLi Therapeutics, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Inflammatory Bowel Disease
Interventions: TD-1473, Itraconazole; Drug
Lead sponsor: Theravance Biopharma; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Healthy
Interventions: Lu AG06466, Itraconazole; Drug
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Healthy Participants
Interventions: AZD5004, Itraconazole, EE/LNG; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Cystic Fibrosis
Interventions: Lumacaftor, Ivacaftor, Ciprofloxacin, Itraconazole, Rifampin; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2013
U.S. locations: 1
States / cities: Evansville, Indiana

Conditions: Healthy
Interventions: LY3537982, Itraconazole, Carbamazepine; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 2
States / cities: San Antonio, Texas • Salt Lake City, Utah

Conditions: Candidiasis, Oral, HIV Infections
Interventions: Itraconazole; Drug
Lead sponsor: Janssen, LP; Industry
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 18
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Berkeley, California + 13 more

Conditions: Healthy Participants
Interventions: INCB161734, Itraconazole, Rifampin, Esomeprazole, Famotidine; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Pharmacokinetics
Interventions: CC-220, Rifampin, Itraconazole; Drug
Lead sponsor: Celgene Corporation; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Healthy
Interventions: LY4100511 (DC-853), Itraconazole, Fluconazole, Carbamazepine; Drug
Lead sponsor: DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Healthy Volunteer
Interventions: ABBV-1088, Placebo for ABBV-1088, Itraconazole (ITZ); Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: Anaheim, California • Grayslake, Illinois

Conditions: Lung Transplant Infection
Interventions: Tolsura; Drug
Lead sponsor: Hong Nguyen; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Nemiralisib, Itraconazole; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Advanced Solid Tumors
Interventions: Tesetaxel, Itraconazole, Rifampin; Drug
Lead sponsor: Odonate Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 3
States / cities: Grand Rapids, Michigan • Dallas, Texas • San Antonio, Texas

Conditions: Healthy
Interventions: LY3509754, Placebo, Itraconazole, Midazolam; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 104 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 2
States / cities: Anaheim, California • Dallas, Texas

Conditions: Basal Cell Carcinoma
Interventions: Itraconazole; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy
Interventions: Lazertinib, Itraconazole, Rifampin; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Prostate Cancer, Prostatic Neoplasms, Castrate-resistant Prostate Cancer (CRPC), Androgen-insensitive Prostate Cancer, Hormone-refractory Prostate Cancer, Metastatic Disease
Interventions: Itraconazole; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Stanford, California

Conditions: Healthy
Interventions: PF-07081532, Cyclosporine, Itraconazole; Drug · Device
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Gastroesophageal Junction Carcinoma
Interventions: Itraconazole; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 7
States / cities: Palo Alto, California • Ann Arbor, Michigan • Durham, North Carolina + 4 more

Search by objective public record fields.

A Study to Determine the Effects of Itraconazole on the Pharmacokinetics (PK) of DS-8500 in Healthy Subjects

Itraconazole to Prevent Recurrent Barrett's Esophagus

Short and Long-term Safety of Micafungin and Other Parenteral Antifungal Agents

Itraconazole as a Targeted Therapy for Inhibiting Hedgehog Pathway Signaling in Esophageal Cancer Patients

A PK Study of IkT-148009 in Older and Elderly Healthy Subjects

Food-effect, Drug-Drug Interaction (DDI), and Formulation Bridging Study

Study That Evaluates the Effect of CYP3A4 Inhibition on Lu AG06466 in Healthy Men and Women

A Study to Investigate the Impact of Multiple Doses of Itraconazole on AZD5004 in Healthy Participants and Multiple Doses of AZD5004 on Combined Oral Ethinyl Oestradiol and Levonorgestrel in Healthy Female Participants

A Phase 1 Study to Examine the Drug-Drug Interaction of Ciprofloxacin, Itraconazole, and Rifampin on the Combination of Lumacaftor With Ivacaftor in Healthy Adult Subjects

A Study of the Effects of Itraconazole or Carbamazepine on LY3537982 in Healthy Participants

An Open Study of the Effect of Itraconazole Oral Solution for the Treatment of Fluconazole Refractory Oropharyngeal Candidiasis in HIV-Positive Subjects.

A Study to Assess the Effect of Itraconazole, Rifampin, and Acid-Reducing Agents on INCB161734 Pharmacokinetics When Administered Orally in Healthy Participants

Study to Evaluate the Effect of Cytochrome P450 (CYP) 3A Inhibition and Induction on the Pharmacokinetics of CC-220 in Healthy Subjects

A Study to Assess LY4100511 (DC-853) in Healthy Adult Participants

A Study to Assess Multiple Ascending Dose, Drug-Drug Interaction, and Asian Pharmacokinetic Study of ABBV-1088

Evaluation of Tolsura When Used as Prophylaxis After Lung Transplantation

A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics (PK) of Nemiralisib

The Effect of Tesetaxel on the QTc Interval and the Effect of Food, Itraconazole, and Rifampin on Tesetaxel Pharmacokinetics in Patients With Advanced Solid Tumors

A Study of LY3509754 in Healthy Non-Japanese and Japanese Participants

Topical Itraconazole in the Treatment of Basal Cell Carcinoma

A Study to Assess the Effects of Itraconazole and Rifampin on Lazertinib in Healthy Adult Participants

Study of Itraconazole in Castrate-resistant Prostate Cancer (CRPC) Post-chemotherapy

A Drug-Drug Interaction Study to Examine the Impact of Itraconazole and Cyclosporine on PF-07081532 Pharmacokinetics in Overweight or Obese Adults

A Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Esophageal Cancer